Mutual Recognition Procedure (MRP): How It Works

Introduction

The Mutual Recognition Procedure (MRP) is one of the principal European procedures for obtaining marketing authorisations in additional Member States when the medicinal product is already authorised in at least one Member State.

Its defining feature is therefore the existence of an existing national marketing authorisation that forms the starting point for recognition in other Member States.

MRP should not be confused with the decentralised procedure. In a DCP, the relevant Member States participate in an assessment before the product has been authorised nationally in those participating Member States. In an MRP, one Member State already has the marketing authorisation and acts as the Reference Member State (RMS) for the recognition procedure.

The procedure is a useful example of how the EU medicines system combines national legal authorisations with common European regulatory coordination. The resulting marketing authorisations remain national authorisations; MRP does not create a single Union marketing authorisation.

The detailed division of responsibilities between the RMS and Concerned Member States (CMSs) is addressed separately in Reference Member State (RMS) and Concerned Member States (CMS): Roles and Responsibilities. The mechanism for unresolved disagreement is addressed in What Happens When Member States Disagree During an MRP or DCP?

1. The Defining Feature of MRP

The simplest way to understand MRP is to start with the regulatory state of the product.

Before MRP begins:

• the product has an existing national marketing authorisation in a Member State;
• that Member State is normally designated as the RMS for the procedure; and
• the MAH seeks recognition of the existing assessment and authorisation in one or more additional Member States.

The participating additional Member States are the CMSs.

Conceptually:

Existing national MA
        |
        v
Reference Member State
        |
        v
Recognition procedure
        |
   +----+----+
   |         |
   v         v
 CMS 1     CMS 2 ...
   |         |
   +----+----+
        |
        v
 National MAs in participating CMSs

This is a conceptual representation rather than a substitute for the legal procedure.

2. Why Does the EU Use Mutual Recognition?

Without a coordinated recognition mechanism, an MAH seeking to market the same nationally authorised medicine in several Member States could face repeated regulatory assessments of substantially the same scientific dossier.

MRP provides a mechanism through which the assessment associated with an existing national authorisation can be recognised by other participating Member States, subject to the conditions established by EU pharmaceutical legislation.

The underlying principle is therefore regulatory cooperation rather than creation of a new centralised authorisation.

The procedure also illustrates an important feature of the EU medicines system: national competence and European cooperation can operate together.

3. The Legal Foundation

The principal legal framework for MRP is found in Directive 2001/83/EC, as amended, particularly the provisions governing mutual recognition and the coordination of national marketing authorisations.

The applicable provisions should always be read in their current consolidated form together with relevant CMDh guidance and procedure-specific requirements.

The legal framework establishes the conditions under which Member States recognise the assessment performed by another Member State and the mechanisms available when a Member State considers that recognition cannot occur because of a relevant public-health concern.

The detailed legal consequences of disagreement are important and are addressed separately rather than being treated as part of routine MRP.

4. RMS and CMS: The Basic Roles

The Reference Member State is the Member State whose existing assessment forms the basis of the MRP.

The Concerned Member States are the Member States in which the MAH seeks recognition of that assessment and the resulting national authorisation.

The terms are procedural roles, not names of permanent regulatory authorities.

A national competent authority can act as an RMS in one procedure and as a CMS in another.

The detailed responsibilities of these roles should not be reduced to the idea that the RMS “does all the work” while the CMSs simply approve the outcome. CMSs participate in the regulatory process and have defined responsibilities under the applicable legislation and procedure.

5. What the MAH Is Trying to Achieve

The MAH's objective is to obtain national marketing authorisations in additional Member States using the existing regulatory assessment as the basis for recognition.

The application therefore has a dual character:

1. it relies on an existing national regulatory history; and
2. it initiates a coordinated recognition process in the additional Member States.

The MAH must ensure that the regulatory dossier, existing authorisation and proposed product information are sufficiently coherent for the participating authorities to assess the application within the MRP framework.

6. The Assessment Report as the Regulatory Foundation

A central document in MRP is the assessment report prepared by the RMS.

The assessment report explains the scientific and regulatory basis for the existing authorisation and provides the CMSs with the assessment on which recognition is sought.

It should not be thought of merely as an administrative attachment. It is an important part of the scientific record that allows the participating authorities to understand the basis of the RMS's assessment.

The exact content and procedural handling of the assessment report depend on the applicable requirements and type of procedure.

7. What Is Being Recognised?

MRP is sometimes described too simply as one country accepting another country's “approval”.

The procedure is more precise than that.

The participating Member States operate within a common EU legal framework and consider the assessment and regulatory documentation generated through the procedure. Recognition takes place subject to the legal conditions governing the procedure.

The objective is not to make the CMS abandon its regulatory responsibilities. Rather, the EU framework establishes a structured basis for mutual recognition while providing mechanisms for addressing circumstances in which recognition cannot proceed normally.

8. The MRP Application

The MAH submits the application through the applicable regulatory framework and identifies the RMS and CMSs involved in the procedure.

The regulatory package must correspond to the existing authorisation and the proposed national authorisations.

In practical terms, the MAH should establish before submission:

• the exact products and presentations concerned;
• the existing national authorisation;
• the RMS;
• the proposed CMSs;
• the relevant regulatory history;
• the applicable product information; and
• any procedural requirements specific to the application.

A clear regulatory baseline is essential. An MRP cannot be interpreted correctly if the starting national authorisation is not understood.

9. The Recognition Process

At a high level, the procedure can be understood as:

Existing national authorisation
          ↓
MRP application
          ↓
RMS assessment documentation
          ↓
CMS review
          ↓
Questions / comments where applicable
          ↓
Recognition or unresolved concern
          ↓
National authorisations

The actual procedural steps, communications and statutory periods depend on the applicable legislation and current procedural guidance.

The diagram is therefore a learning model, not a procedural timetable.

10. The Role of CMS Review

CMSs review the documentation within the MRP framework and consider whether the existing assessment can be recognised in accordance with the applicable legal requirements.

CMS involvement is therefore substantive, even though the RMS has the coordinating role.

Where questions arise, the regulatory process provides mechanisms for clarification and discussion.

The MAH should maintain a controlled record of questions, responses, supporting evidence and final positions because the procedural history can become important if an issue remains unresolved.

11. Product Information During MRP

The product information must be considered as part of the regulatory package.

The MAH should ensure that the proposed information is consistent with the assessment and existing authorisation and that any differences required by the procedure or national implementation are appropriately managed.

MRP should not be understood as simply copying an existing national document into another Member State without regulatory review.

The applicable EU and national requirements determine how the authorised product information is established and implemented.

12. When MRP Proceeds Normally

When the participating Member States can recognise the assessment within the applicable legal framework, the procedure proceeds toward national authorisations in the CMSs.

The resulting authorisations are national legal acts.

This point is important because the MRP creates coordinated national authorisations rather than one European Commission marketing authorisation.

The product can therefore have several national marketing authorisations resulting from a common European procedure.

13. When a Member State Raises a Serious Concern

Mutual recognition is not an unconditional requirement to accept every assessment in every circumstance.

EU pharmaceutical legislation provides a mechanism for a Member State to raise a concern where the applicable legal conditions are met, including circumstances involving a potential serious risk to public health.

This is not the same as an ordinary scientific question or request for clarification.

A regulatory professional should distinguish among:

• routine questions or comments;
• issues that can be resolved within the procedure; and
• a substantive disagreement that engages the formal mechanisms for unresolved concerns.

The latter can lead to the CMDh and, where the legal conditions are satisfied, the Article 29(4) procedure.

That pathway is covered in detail in the dedicated disagreement and Article 29(4) articles.

14. MRP and the Marketing Authorisation Holder

The MAH remains responsible for managing its regulatory submission and ensuring that the information supplied to the authorities is accurate, coherent and appropriately supported.

A practical MRP governance model should maintain traceability between:

• the existing authorisation;
• the regulatory dossier;
• the RMS assessment;
• CMS questions and comments;
• MAH responses;
• agreed product information; and
• the resulting national authorisations.

For products with pharmacovigilance implications, the MAH should also ensure that regulatory changes are connected to the pharmacovigilance system and product-safety information.

15. MRP Is a Recognition Procedure, Not a New Centralised Assessment

The most useful mental model is that MRP extends an existing national regulatory assessment into additional Member States through a legally defined recognition process.

It is therefore different from:

• the centralised procedure, which results in a Union marketing authorisation;
• the DCP, which coordinates an assessment before the relevant national authorisations are granted; and
• a purely national procedure, in which one Member State assesses and authorises the product without using MRP to obtain additional national authorisations.

These distinctions should be established before interpreting procedural documents or regulatory histories.

Key Takeaways

1. MRP starts from an existing national marketing authorisation.
2. The Member State with the relevant existing authorisation acts as the RMS for the procedure.
3. Additional participating Member States are CMSs.
4. MRP is based on mutual recognition within the common EU pharmaceutical framework.
5. The assessment report is an important part of the scientific and regulatory basis for recognition.
6. CMSs have substantive regulatory roles; they are not simply passive recipients of the RMS assessment.
7. Successful MRP results in national marketing authorisations in the participating Member States, not a single Union marketing authorisation.
8. Routine questions and comments should be distinguished from a formal unresolved public-health concern.
9. A potential serious risk to public health can trigger the formal disagreement mechanisms established by EU legislation.
10. Article 29(4) is a distinct subsequent procedure and should not be confused with routine MRP.
11. The MAH should maintain traceability across the existing authorisation, assessment, questions, responses, product information and national authorisations.
12. The detailed RMS/CMS responsibilities and disagreement pathway are treated separately in this series.

16. The MRP Assessment in More Detail

The practical value of MRP lies in the structured use of an existing scientific and regulatory assessment rather than requiring the same application to be reassessed independently in every participating Member State.

The assessment available to the CMSs should allow them to understand the basis on which the RMS considers the product to satisfy the applicable requirements. The MAH therefore needs to maintain consistency between the underlying dossier, the existing national authorisation and the material submitted for recognition.

This is particularly important when the original authorisation is old or has subsequently been modified. The regulatory starting point is not necessarily the dossier as it existed at the time of the original authorisation. The MAH must establish the current authorised position and the regulatory history relevant to the MRP.

17. Regulatory History Matters

Before an MRP submission, the MAH should reconstruct the regulatory history of the product sufficiently to identify changes that affect the assessment being recognised.

Relevant history can include:

• previous variations;
• extensions or other regulatory changes, where applicable;
• previous safety-related changes;
• changes to product information;
• transfers of the marketing authorisation;
• previous MRP or DCP procedures; and
• unresolved or previously discussed regulatory issues.

The purpose is not to reproduce the entire corporate history of the product. It is to ensure that the regulatory package presented to the CMSs accurately represents the product for which recognition is requested.

18. Questions, Comments and Scientific Discussion

The CMS review can identify questions or comments requiring clarification.

These should be distinguished from a formal objection based on the legal grounds for preventing normal recognition.

A question may concern the interpretation of data, an aspect of the dossier, the product information or another element of the assessment. The MAH should respond directly and provide the supporting evidence needed to resolve the issue.

Good regulatory practice requires the company to preserve the distinction between:

1. the question raised by the authority;
2. the evidence supplied by the MAH;
3. the MAH's interpretation of that evidence; and
4. the resulting regulatory position.

This distinction becomes particularly important if the issue later develops into a formal disagreement.

19. What Happens When Recognition Is Not Contested?

Where the procedure proceeds without a formal unresolved concern, the participating Member States move toward granting the corresponding national marketing authorisations in accordance with the applicable procedure.

The legal acts remain national. The common procedure coordinates the scientific and regulatory assessment, but it does not transform those national authorisations into a centrally authorised medicinal product.

The MAH should therefore maintain a country-specific record of the resulting authorisations and their effective product information.

20. National Implementation After MRP

Completion of the European coordination phase does not eliminate the need for national regulatory implementation.

The MAH must manage the resulting national authorisations and comply with the applicable requirements in each Member State.

The precise implementation steps depend on the legal framework and the nature of the product and procedure. The company should therefore avoid assuming that every national administrative step is identical merely because the underlying MRP was common.

For pharmacovigilance purposes, the resulting national authorisations and authorised product information should be incorporated into the company's controlled product and safety-information records.

21. MRP Compared With DCP

MRP and DCP are often confused because both involve an RMS, CMSs and coordinated assessment.

The decisive difference is the regulatory starting point.

The table is a conceptual comparison. The applicable legislation and procedure-specific documents govern individual cases.

A detailed explanation of the DCP is provided in Decentralised Procedure (DCP): How It Works.

22. MRP Compared With the Centralised Procedure

The centralised procedure and MRP produce fundamentally different legal outcomes.

A successful centralised procedure results in a Union marketing authorisation following the applicable Union decision-making process.

A successful MRP results in national marketing authorisations in the participating Member States through mutual recognition.

The distinction is important when interpreting regulatory responsibility, product information, post-authorisation procedures and the legal effect of subsequent decisions.

The centralised procedure is explained in How the EU Centralised Marketing Authorisation Procedure Works.

23. MRP and Pharmacovigilance

MRP is an authorisation procedure rather than a pharmacovigilance procedure, but it can have direct consequences for the pharmacovigilance system.

The MAH should ensure that the authorised product information resulting from the procedure is reflected accurately in the safety-information framework used by the pharmacovigilance organisation.

Where a regulatory change affects an important identified or potential risk, missing information, contraindications, warnings or other safety information, the change should be assessed within the company's pharmacovigilance processes.

The regulatory procedure itself should not be confused with the subsequent PV activities required by the applicable framework.

24. QPPV Perspective

The QPPV is not the owner of the MRP regulatory procedure simply because the product is subject to pharmacovigilance obligations.

However, the QPPV should have appropriate oversight of pharmacovigilance consequences arising from the procedure.

For a safety-relevant MRP change, useful oversight questions include:

• Does the authorised safety information remain consistent across the relevant records?
• Have changes affecting the safety profile been assessed for PV impact?
• Does the RMP require consideration of the regulatory outcome?
• Are relevant signal-management or aggregate-reporting processes affected?
• Is the implementation traceable?

The exact answer depends on the regulatory outcome. These are governance questions rather than universal procedural requirements.

25. The MAH's Regulatory Control Model

A robust MRP process benefits from a single controlled regulatory record rather than disconnected country files.

A useful conceptual structure is:

Existing national authorisation
             ↓
        MRP strategy
             ↓
       RMS assessment
             ↓
       CMS interactions
             ↓
        MAH responses
             ↓
       Final agreement
             ↓
    National authorisations
             ↓
   Country implementation
             ↓
    Lifecycle maintenance

Each stage should be traceable to the underlying regulatory evidence.

This becomes particularly important when the product subsequently undergoes variations or another regulatory procedure. The MRP record can then provide the historical context needed to understand why the current authorised position exists.

26. Common Errors in Understanding MRP

Treating MRP as a centralised procedure

MRP does not produce a Union marketing authorisation.

Assuming CMSs simply accept everything from the RMS

CMSs have defined roles within the procedure and may raise issues in accordance with the applicable legal framework.

Treating every question as a formal objection

Scientific questions and clarification requests are not automatically equivalent to the formal grounds for unresolved recognition.

Ignoring the existing national authorisation

The existing authorisation is the starting point of MRP. Its current status and regulatory history are therefore fundamental.

Assuming MRP eliminates national regulatory work

The resulting marketing authorisations remain national and require appropriate national regulatory management.

Treating MRP and DCP as the same procedure

Both use coordinated Member State participation, but their starting regulatory positions and procedural purposes differ.

Assuming the QPPV owns the whole procedure

The QPPV's role concerns pharmacovigilance oversight. Ownership of the broader regulatory procedure depends on the company's governance model and responsibilities.

Key Takeaways

1. MRP is built around an existing national marketing authorisation and its regulatory assessment.
2. The MAH should establish the current authorised position and relevant regulatory history before relying on that assessment.
3. CMS review is substantive and should not be reduced to passive acceptance.
4. Questions and comments should be distinguished from formal unresolved concerns.
5. Successful MRP produces coordinated national marketing authorisations rather than a Union authorisation.
6. National implementation remains relevant after the coordinated procedure concludes.
7. MRP differs from DCP primarily in its starting regulatory position and purpose.
8. MRP differs fundamentally from the centralised procedure in the legal nature of the resulting authorisations.
9. Safety-relevant outcomes should be assessed for their pharmacovigilance consequences.
10. The QPPV should oversee relevant PV consequences without being assumed to own the entire regulatory procedure.
11. A traceable regulatory history is valuable for subsequent variations, safety changes and other lifecycle procedures.

References

1. European Parliament and Council. Directive 2001/83/EC on the Community code relating to medicinal products for human use, as amended. Principal legal basis for national marketing authorisations, mutual recognition and decentralised procedures.
2. Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh). CMDh guidance and procedural information for MRP/DCP. Current procedural material concerning national-authorisation coordination and mutual recognition.
3. European Medicines Agency. European regulatory system for medicines. Current explanatory material concerning the interaction between national competent authorities and the European regulatory network.
4. European Medicines Agency. Marketing authorisation procedures. Current explanatory material concerning the centralised procedure and its distinction from national procedures.
5. European Medicines Agency. Referral procedures for human medicines. Current information relevant to the escalation of unresolved concerns from MRP/DCP into applicable Union procedures.
6. European Commission. Pharmaceutical legislation. Current Union legislative material concerning medicinal products for human use.

Primary-document hierarchy

For a live MRP, primary sources should take precedence over general explanatory material. A practical hierarchy is:

1. current consolidated provisions of Directive 2001/83/EC and other applicable legislation;
2. the relevant procedure-specific regulatory documentation;
3. the RMS assessment and associated procedural documents;
4. CMDh procedural positions or recommendations where applicable;
5. national competent-authority decisions and implementation documents; and
6. current EMA, CMDh and European Commission guidance.

The precise document hierarchy depends on the regulatory question being answered. Legal effect should be established from the applicable legislation and legally operative national acts rather than inferred from secondary summaries.

Regulatory Note

This article is an educational explanation of the Mutual Recognition Procedure. It is not legal advice and does not replace the current text of Directive 2001/83/EC, CMDh guidance, national competent-authority requirements or procedure-specific regulatory documentation.

MRP requirements, procedural guidance and national implementation practices may change. For a live application, the current applicable legislation and procedure-specific guidance should be reviewed.

The article deliberately separates the MRP mechanism from the detailed RMS/CMS role allocation and from the formal disagreement and Article 29(4) procedures. Those subjects are addressed in dedicated articles in this series.

The exact procedural steps, periods, documentation and implementation requirements depend on the applicable legal framework and individual procedure. No generic description should be treated as overriding a formal regulatory document or legally operative decision.